OncoMed Pharmaceuticals Company Profile (NASDAQ:OMED)

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OMED
  • CUSIP:
Key Metrics:
  • Previous Close: $9.13
  • 50 Day Moving Average: $8.25
  • 200 Day Moving Average: $9.46
  • 52-Week Range: $7.41 - $15.49
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.53
  • P/E Growth: 0.00
  • Market Cap: $338.65M
  • Outstanding Shares: 37,092,000
  • Beta: 2.81
Profitability:
  • Net Margins: -409.54%
  • Return on Equity: -1,307.23%
  • Return on Assets: -17.68%
Debt:
  • Current Ratio: 3.83%
  • Quick Ratio: 3.83%
Additional Links:
Companies Related to OncoMed Pharmaceuticals:

Analyst Ratings

Consensus Ratings for OncoMed Pharmaceuticals (NASDAQ:OMED) (?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $19.88 (117.69% upside)

Analysts' Ratings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetDetails
12/19/2016SunTrust Banks, Inc.Initiated CoverageBuy$16.00View Rating Details
11/11/2016Leerink SwannReiterated RatingMarket PerformView Rating Details
11/2/2016Cantor FitzgeraldSet Price TargetBuy$16.00View Rating Details
11/2/2016HC WainwrightReiterated RatingBuyView Rating Details
8/10/2016Jefferies Group LLCBoost Price TargetBuy$15.00 -> $16.00View Rating Details
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00View Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$20.00View Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00View Rating Details
12/3/2015Wells Fargo & CoInitiated CoverageOutperformView Rating Details
6/2/2015Piper Jaffray CompaniesSet Price TargetBuy$43.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2017        
11/1/2016Q3($0.77)($0.77)$9.48 million$5.92 millionViewN/AView Earnings Details
8/9/2016Q216($0.81)($0.91)$8.09 million$6.67 millionViewN/AView Earnings Details
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details
11/4/2014($0.30)($0.18)ViewN/AView Earnings Details
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.47)ViewN/AView Earnings Details
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoMed Pharmaceuticals (NASDAQ:OMED)
Current Year EPS Consensus Estimate: $-3.24 EPS
Next Year EPS Consensus Estimate: $-1.65 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)$1.15($0.21)
Q2 20161($0.87)($0.87)($0.87)
Q3 20162($0.74)($0.69)($0.72)
Q4 20162($0.81)($0.70)($0.76)
Q1 20171($0.82)($0.82)($0.82)
Q2 20171($0.30)($0.30)($0.30)
Q3 20171($0.32)($0.32)($0.32)
Q4 20171($0.33)($0.33)($0.33)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoMed Pharmaceuticals (NASDAQ:OMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Insider Ownership Percentage: 41.25%
Institutional Ownership Percentage: 42.24%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2017Paul J. HastingsCEOSell42,738$8.34$356,434.92View SEC Filing  
1/3/2017John A. LewickiEVPSell9,175$7.63$70,005.25View SEC Filing  
1/3/2017Timothy HoeySVPSell12,763$7.64$97,509.32View SEC Filing  
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for OncoMed Pharmaceuticals (NASDAQ:OMED)
DateHeadline
News IconStock Levels in Review for OncoMed Pharmaceuticals Inc (OMED) - Davidson Register (NASDAQ:OMED)
davidsonregister.com - February 22 at 9:04 AM
News IconAnalysts Peer Into Their Crystal Balls For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED): Where Is It headed? - Winfield Review (NASDAQ:OMED)
winfieldreview.com - February 22 at 9:04 AM
seekingalpha.com logoMore From The Biotech Q&A Mailbag (NASDAQ:OMED)
seekingalpha.com - February 21 at 5:52 PM
sbwire.com logo"Liver Cancer - Pipeline Review, H2 2016" Now Available at Fast Market Research (NASDAQ:OMED)
www.sbwire.com - February 20 at 9:40 AM
News IconChecking in on the Numbers for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - BVN (NASDAQ:OMED)
bvnewsjournal.com - February 18 at 11:47 AM
News IconAre Analysts Optimistic About Where OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is Heading? - Winfield Review (NASDAQ:OMED)
winfieldreview.com - February 18 at 11:47 AM
News IconOncoMed Pharmaceuticals Inc OMED Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:OMED)
www.bioportfolio.com - February 17 at 4:42 PM
News IconInvestors are Watching Shares of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Searcy News (NASDAQ:OMED)
searcysentinel.com - February 17 at 8:12 AM
News IconMarket Update on Shares of Oncomed Pharmaceuticals Inc. (OMED) - BVN (NASDAQ:OMED)
bvnewsjournal.com - February 17 at 8:12 AM
bizjournals.com logoFrom Wnt it came: Stealthy biotech grabs $33 million Series A (NASDAQ:OMED)
www.bizjournals.com - February 16 at 6:36 PM
streetinsider.com logoOncoMed Pharma (OMED) Enrolled, Dosed First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody (NASDAQ:OMED)
www.streetinsider.com - February 14 at 1:16 AM
openpr.com logoBiopharmaceuticals and Biomedicine Market – Trends, Outlook, and Opportunity Analysis, 2016-2024 (NASDAQ:OMED)
www.openpr.com - February 13 at 8:14 PM
streetinsider.com logoOncoMed Pharma (OMED) Enrolled, Dosed First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific ... - StreetInsider.com (NASDAQ:OMED)
www.streetinsider.com - February 13 at 9:37 AM
finance.yahoo.com logoOncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer (NASDAQ:OMED)
finance.yahoo.com - February 13 at 9:37 AM
nasdaq.com logoOncoMed Pharmaceuticals to Present at the BIO CEO and Investor ... - Nasdaq (NASDAQ:OMED)
www.nasdaq.com - February 9 at 5:58 AM
News IconNoteworthy Wednesday Option Activity: OMED, ZEN, FMI (NASDAQ:OMED)
www.stockoptionschannel.com - February 8 at 7:57 PM
finance.yahoo.com logoOncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences (NASDAQ:OMED)
finance.yahoo.com - February 8 at 7:57 PM
capitalcube.com logoOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : February 1, 2017 (NASDAQ:OMED)
www.capitalcube.com - February 1 at 8:09 PM
investornewswire.com logoOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Records An Impact Score Of 41 - Investor Newswire (NASDAQ:OMED)
www.investornewswire.com - January 30 at 8:45 AM
News IconMarket Focus - Tracking These Shares: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Gilbert Daily (NASDAQ:OMED)
gilbertdaily.com - January 30 at 8:45 AM
News IconEarnings in Full Force, Analysts Take Aim at OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Wall Street Beacon (NASDAQ:OMED)
wsbeacon.com - January 27 at 12:06 AM
News IconChart Level Analysis on Shares of Oncomed Pharmaceuticals Inc. (OMED) - Sherwood Daily (NASDAQ:OMED)
sherwooddaily.com - January 25 at 12:50 AM
News IconAs Oncomed Pharmaceuticals INC (OMED) Market Value Declined, Shareholder Bvf INC Has Raised Holding (NASDAQ:OMED)
randolphguide.com - January 23 at 7:20 PM
News IconMA Watch on Shares of Oncomed Pharmaceuticals Inc. (OMED) - Rives Journal (NASDAQ:OMED)
rivesjournal.com - January 21 at 12:49 AM
finance.yahoo.com logoOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Brontictuzumab for the Treatment of Metastatic Colorectal Cancer Patients (NASDAQ:OMED)
finance.yahoo.com - January 20 at 7:49 PM
News IconBiotech Is Hot And Oncomed Pharmaceuticals Inc. (NASDAQ:OMED)... - Small Cap Exclusive (press release) (NASDAQ:OMED)
smallcapexclusive.com - January 17 at 7:24 PM
News IconOncoMed Pharmaceuticals Inc OMED Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:OMED)
www.bioportfolio.com - January 17 at 11:17 AM
News IconWill The Needle Move For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:OMED)
wsbeacon.com - January 13 at 8:18 AM
prnewswire.com logoForSight VISION4, Inc. Announces Acquisition by Roche (NASDAQ:OMED)
www.prnewswire.com - January 11 at 12:54 AM
capitalcube.com logoOncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : January 10, 2017 (NASDAQ:OMED)
www.capitalcube.com - January 10 at 7:54 PM
News IconReady for an Upsurge? Analysts Chime in on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Prospect Journal (NASDAQ:OMED)
prospectjournal.com - January 10 at 8:39 AM
capitalcube.com logoOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : January 9, 2017 (NASDAQ:OMED)
www.capitalcube.com - January 9 at 7:44 PM
streetinsider.com logoOncoMed Pharma (OMED) Doses First Patient in Phase 1b Trial of ... - StreetInsider.com (NASDAQ:OMED)
www.streetinsider.com - January 6 at 4:17 AM
biz.yahoo.com logoONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosu (NASDAQ:OMED)
biz.yahoo.com - January 5 at 11:14 PM
publicnow.com logoOncoMed Announces Year-End Cash Balance and 2017 Outlook (NASDAQ:OMED)
www.publicnow.com - January 5 at 11:14 PM
streetinsider.com logoOncoMed Pharma (OMED) Doses First Patient in Phase 1b Trial of Anti-DLL4/VEGF Bispecific Antibody (NASDAQ:OMED)
www.streetinsider.com - January 4 at 7:50 PM
investingnews.com logoOncoMed Initiates Enrollment of Phase 1b Clinical Trial for Metastatic Colorectal Cancer Patients (NASDAQ:OMED)
investingnews.com - January 4 at 7:50 PM
publicnow.com logoOncoMed Initiates Enrollment of Phase 1b Clinical Trial of Anti-DLL4/VEGF Bispecific Antibody as Second-line Treatment for Metastatic Colorectal Cancer Patients (NASDAQ:OMED)
www.publicnow.com - January 4 at 7:50 PM
News IconAnalysts Projecting Upside, Can This Stock Surge Higher: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Prospect Journal (NASDAQ:OMED)
prospectjournal.com - January 3 at 10:26 AM
finance.yahoo.com logoAre Options Traders Betting on a Big Move in OncoMed (OMED) Stock? (NASDAQ:OMED)
finance.yahoo.com - December 27 at 9:55 AM
News IconHere's Why Micron Technology (MU) Stock Is Surging Today (NASDAQ:OMED)
rawgistafrica.com - December 23 at 12:21 AM
capitalcube.com logoETFs with exposure to OncoMed Pharmaceuticals, Inc. : December 22, 2016 (NASDAQ:OMED)
www.capitalcube.com - December 22 at 7:19 PM
investornewswire.com logoOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:OMED)
www.investornewswire.com - December 22 at 12:53 AM
investornewswire.com logoOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Records An Impact Score Of 100 - Investor Newswire (NASDAQ:OMED)
www.investornewswire.com - December 22 at 12:53 AM
News IconIndicator Level Summary for Oncomed Pharmaceuticals Inc. (OMED) - Yankee Analysts (NASDAQ:OMED)
yankeeanalysts.com - December 21 at 9:34 AM
News IconRevolution Medicines collects $25 mln (NASDAQ:OMED)
www.pehub.com - December 20 at 6:20 PM
News IconREVOLUTION Medicines Raises Additional $25 Million in Series A Financing (NASDAQ:OMED)
www.enhancedonlinenews.com - December 20 at 6:20 PM
News IconUpside Alert: Delving into Shares of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Prospect Journal (NASDAQ:OMED)
prospectjournal.com - December 20 at 1:19 PM
finance.yahoo.com logoCoverage initiated on OncoMed Pharma by SunTrust (NASDAQ:OMED)
finance.yahoo.com - December 20 at 1:19 PM
News IconOncoMed Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 (NASDAQ:OMED)
www.bioportfolio.com - December 14 at 7:45 PM

Social

What is OncoMed Pharmaceuticals' stock symbol?

OncoMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

Where is OncoMed Pharmaceuticals' stock going? Where will OncoMed Pharmaceuticals' stock price be in 2017?

8 analysts have issued 1 year target prices for OncoMed Pharmaceuticals' shares. Their forecasts range from $13.00 to $40.00. On average, they expect OncoMed Pharmaceuticals' stock price to reach $19.88 in the next twelve months.

When will OncoMed Pharmaceuticals announce their earnings?

OncoMed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.

What are analysts saying about OncoMed Pharmaceuticals stock?

Here are some recent quotes from research analysts about OncoMed Pharmaceuticals stock:

  • According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (1/11/2017)

  • HC Wainwright analysts commented, "We believe a positive readout from the Phase 2 YOSEMITE trial in pancreatic cancer could lead partner Celgene to opt-in to the demcizumab program in early 2017, followed by readout from the Phase 2 DENALI trial in NSCLC a year later," analyst Shaunak Deepak wrote in a note.Related Link: Shkreli Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial FailMeanwhile, the upcoming data of vantictumab in breast cancer patients could drive Bayer's opt-in to the Wnt program in 2017."We regard the pancreatic cancer indication as a source of potential upside for our vantictumab estimates. We see the second Wnt pathway antagonist ipafricept as a source of potential upside," Deepak highlighted.Further, the analyst expects GlaxoSmithKline may opt-in to develop tarextumab, as it may show activity in lung cancer despite the compound failed in pancreatic cancer trial."In addition to near-term opt-in milestones that could reach $172 million, we believe these partnerships could payoff with long-term benefits and free-up OncoMed's resources to pursue new development activities," (9/22/2016)

Who owns OncoMed Pharmaceuticals stock?

OncoMed Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.70%), Franklin Resources Inc. (2.60%), Alyeska Investment Group L.P. (1.86%), Renaissance Technologies LLC (1.27%), State Street Corp (0.92%) and Disciplined Growth Investors Inc. MN (0.88%). Company insiders that own OncoMed Pharmaceuticals stock include Alicia J Hager, Austin Gurney, Jack W Lasersohn, Jakob Dupont, John A Lewicki, Paul J Hastings, Sunil Patel and Timothy Hoey.

Who sold OncoMed Pharmaceuticals stock? Who is selling OncoMed Pharmaceuticals stock?

OncoMed Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Turner Investments LLC, Franklin Resources Inc. and Hodges Capital Management Inc.. Company insiders that have sold OncoMed Pharmaceuticals stock in the last year include John A Lewicki, Paul J Hastings and Timothy Hoey.

Who bought OncoMed Pharmaceuticals stock? Who is buying OncoMed Pharmaceuticals stock?

OncoMed Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, FMR LLC, State Street Corp and Disciplined Growth Investors Inc. MN.

How do I buy OncoMed Pharmaceuticals stock?

Shares of OncoMed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of OncoMed Pharmaceuticals stock cost?

One share of OncoMed Pharmaceuticals stock can currently be purchased for approximately $9.13.

OncoMed Pharmaceuticals (NASDAQ:OMED) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)

Earnings History Chart

Earnings by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)

Dividend History Chart

Dividend Payments by Quarter for OncoMed Pharmaceuticals (NASDAQ:OMED)

Last Updated on 2/25/2017 by MarketBeat.com Staff